160 related articles for article (PubMed ID: 23928249)
21. Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast.
Lenkinski RE; Wang X; Elian M; Goldberg SN
Magn Reson Med; 2009 Jun; 61(6):1286-92. PubMed ID: 19365855
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of breast cancer using proton MR spectroscopy: total choline peak integral and signal-to-noise ratio as prognostic indicators.
Shin HJ; Baek HM; Cha JH; Kim HH
AJR Am J Roentgenol; 2012 May; 198(5):W488-97. PubMed ID: 22528931
[TBL] [Abstract][Full Text] [Related]
23. 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors.
Tozaki M; Hoshi K
AJR Am J Roentgenol; 2010 May; 194(5):1384-90. PubMed ID: 20410429
[TBL] [Abstract][Full Text] [Related]
24. In vivo proton spectroscopy of giant cell tumor of the bone.
Sah PL; Sharma R; Kandpal H; Seith A; Rastogi S; Bandhu S; Jagannathan NR
AJR Am J Roentgenol; 2008 Feb; 190(2):W133-9. PubMed ID: 18212197
[TBL] [Abstract][Full Text] [Related]
25. Human breast lesions: characterization with proton MR spectroscopy.
Roebuck JR; Cecil KM; Schnall MD; Lenkinski RE
Radiology; 1998 Oct; 209(1):269-75. PubMed ID: 9769842
[TBL] [Abstract][Full Text] [Related]
26. Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS.
Shin HJ; Baek HM; Ahn JH; Baek S; Kim H; Cha JH; Kim HH
NMR Biomed; 2012 Dec; 25(12):1349-59. PubMed ID: 22566277
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic usefulness of water-to-fat ratio and choline concentration in malignant and benign breast lesions and normal breast parenchyma: an in vivo (1) H MRS study.
Thakur SB; Brennan SB; Ishill NM; Morris EA; Liberman L; Dershaw DD; Bartella L; Koutcher JA; Huang W
J Magn Reson Imaging; 2011 Apr; 33(4):855-63. PubMed ID: 21448950
[TBL] [Abstract][Full Text] [Related]
28. Proton (1H) MR spectroscopy of the breast.
Bartella L; Huang W
Radiographics; 2007 Oct; 27 Suppl 1():S241-52. PubMed ID: 18180230
[TBL] [Abstract][Full Text] [Related]
29. Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T.
Baik HM; Su MY; Yu H; Mehta R; Nalcioglu O
MAGMA; 2006 May; 19(2):96-104. PubMed ID: 16779565
[TBL] [Abstract][Full Text] [Related]
30. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters.
Sitter B; Lundgren S; Bathen TF; Halgunset J; Fjosne HE; Gribbestad IS
NMR Biomed; 2006 Feb; 19(1):30-40. PubMed ID: 16229059
[TBL] [Abstract][Full Text] [Related]
31. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI).
Danishad KK; Sharma U; Sah RG; Seenu V; Parshad R; Jagannathan NR
NMR Biomed; 2010 Apr; 23(3):233-41. PubMed ID: 20175134
[TBL] [Abstract][Full Text] [Related]
32. MRI and (1)H MRS of the breast: presence of a choline peak as malignancy marker is related to K21 value of the tumor in patients with invasive ductal carcinoma.
Geraghty PR; van den Bosch MA; Spielman DM; Hunjan S; Birdwell RL; Fong KJ; Stables LA; Zakhour M; Herfkens RJ; Ikeda DM
Breast J; 2008; 14(6):574-80. PubMed ID: 19000051
[TBL] [Abstract][Full Text] [Related]
33. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy.
Mackinnon WB; Barry PA; Malycha PL; Gillett DJ; Russell P; Lean CL; Doran ST; Barraclough BH; Bilous M; Mountford CE
Radiology; 1997 Sep; 204(3):661-6. PubMed ID: 9280241
[TBL] [Abstract][Full Text] [Related]
34. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy?
Tozaki M; Fukuma E
AJR Am J Roentgenol; 2009 Sep; 193(3):840-9. PubMed ID: 19696300
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases.
Yeung DK; Yang WT; Tse GM
Radiology; 2002 Oct; 225(1):190-7. PubMed ID: 12355004
[TBL] [Abstract][Full Text] [Related]
36. 31P MRSI and 1H MRS at 7 T: initial results in human breast cancer.
Klomp DW; van de Bank BL; Raaijmakers A; Korteweg MA; Possanzini C; Boer VO; van de Berg CA; van de Bosch MA; Luijten PR
NMR Biomed; 2011 Dec; 24(10):1337-42. PubMed ID: 21433156
[TBL] [Abstract][Full Text] [Related]
37. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
Cao MD; Sitter B; Bathen TF; Bofin A; Lønning PE; Lundgren S; Gribbestad IS
NMR Biomed; 2012 Feb; 25(2):369-78. PubMed ID: 21823183
[TBL] [Abstract][Full Text] [Related]
38. What is new in breast MRI spectroscopy.
Nelson MT; Bolan PJ; Garwood M; Everson L; Emory T; Kuehn-Hajder J
Eur J Radiol; 2012 Sep; 81 Suppl 1():S107-8. PubMed ID: 23083548
[No Abstract] [Full Text] [Related]
39. [Proton magnetic resonance spectroscopy in the diagnosis of breast cancer].
Meladze NV; Kuchuk PV; Abduraimov AB; Les'ko KA; Shariia MA; Malik DS; Matkhev S; Boĭko EA
Vestn Rentgenol Radiol; 2011; (4):31-6. PubMed ID: 22288145
[TBL] [Abstract][Full Text] [Related]
40. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts.
Morse DL; Raghunand N; Sadarangani P; Murthi S; Job C; Day S; Howison C; Gillies RJ
Magn Reson Med; 2007 Aug; 58(2):270-80. PubMed ID: 17654590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
